Key points from article :
Porphyromonas gingivalis has been linked with many diseases, especially inflammaging.
P. gingivalis has been implicated in a 13.6 times increase in risk of heart attack.
“It initiate and advance atherosclerosis, heart disease and alzheimer’s disease" - Daniel Sindelar, CEO of Keystone Bio.
St Louis-based biotech start-up Keystone Bio target this pathogen with a new biologic.
PrevEvent, a topical monoclonal antibody, has been demonstrated to eliminate P. gingivalis for up to a year.
It stops production of the deadly exotoxins, reversing and preventing a large catalogue of our most deadly diseases.
The company is initiating a Phase I a/b clinical trial to establish efficacy for reversing systemic inflammation and associated inflammatory biomarkers.
Keystone is also advancing two other programs – a diagnostic test and a preventive vaccine.
"If we do not eliminate P. gingivalis, we are potentially running a futile race" - Sindelar.
